Tom Doyle joined Kura in 2021 with more than 20 years of experience in the biotechnology, pharmaceutical and healthcare industries, leading finance teams from early-stage development through commercialization. Most recently, he was Vice President of Finance at Zogenix, Inc., supporting the clinical trials and launch of multiple therapies since 2013. Prior to Zogenix, Mr. Doyle was the Controller for Peregrine Pharmaceuticals, an oncology development and biomanufacturing company. He has also served as the Director of Revenue and Cost Accounting at ISTA Pharmaceuticals and the Director of Internal Audit and R&D Finance at Valeant Pharmaceuticals. Mr. Doyle is a certified public accountant and received his MBA from California State University San Marcos and his Bachelor of Science in finance from San Diego State University.